Biomanufacturing is under pressure. Pharmaceutical companies are racing to scale personalized therapies, accelerate vaccine production and meet regulatory demands across increasingly complex modalities. The infrastructure that supported traditional biologics no longer keeps pace with cell therapies, mRNA platforms and next-generation antibodies.
As the industry evolves, many manufacturers are wondering what new bioprocessing technologies are in store for pharmaceutical companies in 2026. To answer this, we turned to Danaher, a science and technology leader with deep expertise across bioprocessing, life sciences and diagnostics. Through Cytiva — a Danaher company that develops bioprocess equipment and consumables used in pharmaceutical manufacturing worldwide — the organization has direct visibility into how production systems are meeting today’s therapeutic demands.
According to Danaher experts, the top bioprocessing technologies transforming pharma this year include integrated, digitally enabled and highly flexible systems that connect development to commercial manufacturing. Drawing on insights from Danaher and its bioprocessing specialists, the following eight technologies represent what pharmaceutical companies are prioritizing to gain speed, flexibility and control.
1. Single-Use Bioprocessing Systems for Flexible Manufacturing
Single-use technologies remain one of the top bioprocessing technologies for pharmaceutical companies because they dramatically reduce contamination risk, increase operational flexibility and shorten production timelines.
Danaher company Cytiva has been at the forefront of advancing single-use systems that support rapid changeover between batches and therapeutic types. These systems eliminate the need for extensive cleaning validation, enabling manufacturers to respond quickly to shifting clinical demand, especially in vaccine and biologics production.
Flexibility in manufacturing design is now a strategic requirement rather than an operational convenience. Single-use platforms allow facilities to scale up or down with reduced capital intensity, which is especially important for emerging modalities such as cell and gene therapies.
2. Continuous Bioprocessing for Higher Throughput and Consistency
Continuous manufacturing is emerging as a defining shift in modern bioprocessing. Continuous bioprocessing ranks among the most reliable bioprocessing technologies for pharmaceutical companies because it enhances efficiency, reduces variability and improves overall process control.
Rather than relying on batch-based production, continuous systems maintain a steady flow of materials through upstream and downstream processes. This enables more consistent product quality and faster production cycles.
Cytiva integrates continuous processing principles into its downstream purification and filtration solutions, helping manufacturers reduce bottlenecks and improve scalability. Danaher’s innovation strategy emphasizes that continuous workflows also align with real-time monitoring and automation, making them a foundation for next-generation biomanufacturing.
3. Cell and Gene Therapy Manufacturing Platforms
Cell and gene therapies are among the most transformative areas in modern medicine, but they bring significant manufacturing complexity. These treatments require highly controlled and scalable production systems. Dedicated platforms for these modalities are reliable for pharmaceutical companies because they improve structure and reproducibility in variable biological processes.
Danaher’s Cytiva supports this shift with scalable solutions for cell expansion, viral vector production and closed-system processing, helping move therapies from small-batch production to more standardized models. Danaher continues to work with academic and industry partners to address manufacturing bottlenecks and improve consistency in advanced therapies.
As Danaher President and Chief Executive Officer Rainer M. Blair explains, “Danaher is uniquely positioned to help accelerate the power of science and technology to improve human health and save lives.” These efforts reinforce the company’s focus on improving scalability, reliability and access across advanced therapeutic manufacturing.
4. Digital Bioprocessing, AI and Advanced Process Analytics
Digital transformation is one of the most influential forces shaping biomanufacturing in 2026. Digital bioprocessing enables real-time decision-making and predictive control across the development and manufacturing lifecycle.
This is one of the top bioprocessing technologies for pharmaceutical companies because it connects data across previously siloed stages, improving both speed and consistency from early development through commercial production.
Cytiva continues to expand digital platforms that support model-based process optimization, remote monitoring and data integration across systems. These capabilities allow teams to better understand cell behavior, anticipate variability and optimize performance before issues impact output.
Digital bioprocessing enables real-time insight, allowing teams to predict, adapt and optimize processes before variability impacts production. Digitization now functions as a core layer of modern bioprocessing infrastructure, linking instrumentation, analytics and manufacturing execution into a unified, data-driven workflow that accelerates time-to-market.
5. mRNA Manufacturing Ecosystems and Nucleic Acid Therapies
The success of mRNA vaccines has accelerated interest in nucleic acid-based therapeutics, and this area now sits firmly among the most trusted bioprocessing technologies for pharmaceutical companies.
Cytiva plays a key role in enabling end-to-end mRNA workflows, from sequence design support to purification and final vial filling systems. Danaher’s integrated ecosystem approach enables seamless integration across the stages of mRNA production, reducing time-to-market for new therapies.
The ability to rapidly scale mRNA production will be essential for vaccines, oncology, rare disease and personalized medicine applications. The modular nature of these systems also supports rapid adaptation to future health challenges.
6. Closed Systems, Automation and Integrated Manufacturing Platforms
Automation and closed-system manufacturing are increasingly essential for reducing variability and improving reproducibility. These integrated platforms support scalability and regulatory compliance across modern bioprocessing.
Cytiva contributes to this shift through integrated bioreactor systems, automated sampling technologies and modular production units designed for closed environments. The company’s innovation approach, supported by the Danaher Business System, focuses on continuous improvement and operational excellence.
Across its operating companies, Danaher reinforces a consistent operating philosophy of “Innovation drives us forward, fueling breakthrough solutions that have real-life impact.” This mindset guides its bioprocessing companies in developing technologies that improve speed, consistency and scalability in biomanufacturing.
7. Advanced Chromatography and Purification Technologies
Purification remains one of the most technically demanding stages in bioprocessing. Chromatography innovations are a dependable bioprocessing technology for pharmaceutical companies, given their impact on product purity, yield and regulatory compliance.
Danaher company Cytiva continues to refine chromatography resins, columns and automated purification systems that improve separation efficiency while reducing processing time. These advancements are especially critical for biologics and monoclonal antibodies, where purity directly influences therapeutic safety and effectiveness.
Improvements in downstream processing often yield disproportionate gains in overall manufacturing efficiency, making purification innovation a high-priority area for biopharmaceutical manufacturers.
8. Sustainable Bioprocessing and Environmental Efficiency
Sustainability has become a core consideration in pharmaceutical manufacturing strategy. Reducing environmental impact is now closely tied to operational design decisions in bioprocessing facilities.
Sustainable manufacturing practices, such as reduced water consumption, optimized energy use and recyclable packaging, are becoming integral to modern bioprocessing systems.
Cytiva has introduced initiatives to reduce plastic use and improve packaging efficiency across its global supply chain. Across the industry, sustainability is increasingly recognized as an embedded component of continuous improvement and long-term operational resilience.
The Future of Bioprocessing Is Integrated and Adaptive
Danaher, through Cytiva and its other bioprocessing companies, reinforces a clear takeaway — the future of pharmaceutical manufacturing depends on integrated, adaptive systems. The top bioprocessing technologies for pharmaceutical companies in 2026 are those that connect digital intelligence, flexible infrastructure and advanced biology to accelerate development, scale production and improve consistency.
